Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Risk NMIBC”

95 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 95 results

Not applicableLooking for participantsNCT06991868
What this trial is testing

Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

Who this might be right for
NMIBCMIBCUTUC
Peking University First Hospital 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06630871
What this trial is testing

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Who this might be right for
NMIBC
Fujian Medical University Union Hospital 40
Large-scale testing (Phase 3)UnknownNCT04490993
What this trial is testing

Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-muscle Invasive Bladder Cancer
Jiangsu Yahong Meditech Co., Ltd aka Asieris 359
Early research (Phase 1)Active Not RecruitingNCT05768347
What this trial is testing

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

Who this might be right for
Urothelial CarcinomaNon-Invasive Bladder Urothelial Carcinoma
H. Lee Moffitt Cancer Center and Research Institute 9
Testing effectiveness (Phase 2)UnknownNCT03759496
What this trial is testing

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Hellenic GenitoUrinary Cancer Group 39
Testing effectiveness (Phase 2)Looking for participantsNCT05951179
What this trial is testing

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer
Protara Therapeutics 131
Not applicableLooking for participantsNCT05123625
What this trial is testing

Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC

Who this might be right for
Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University 200
Not applicableNot Yet RecruitingNCT07053748
What this trial is testing

Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy

Who this might be right for
High - Risk NMIBC
Peking University First Hospital 30
Testing effectiveness (Phase 2)WithdrawnNCT02143804
What this trial is testing

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

Who this might be right for
Bladder CancerHigh GradeNon Muscle Invasive
CG Oncology, Inc.
Large-scale testing (Phase 3)Study completedNCT02773849
What this trial is testing

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Superficial Bladder Cancer
Ferring Pharmaceuticals 157
Not applicableEnded earlyNCT04412070
What this trial is testing

Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients

Who this might be right for
Bladder Cancer
Hopital Foch 20
Large-scale testing (Phase 3)Active Not RecruitingNCT05538663
What this trial is testing

Intravesical BCG vs GEMDOCE in NMIBC

Who this might be right for
Non-muscle-invasive Bladder Cancer
ECOG-ACRIN Cancer Research Group 870
Testing effectiveness (Phase 2)Study completedNCT02015104
What this trial is testing

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Who this might be right for
Bladder Cancer
National Cancer Institute (NCI) 32
Not applicableUnknownNCT05547516
What this trial is testing

Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-muscle-invasive Bladder Cancer
First Affiliated Hospital Xi'an Jiaotong University 140
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Large-scale testing (Phase 3)Looking for participantsNCT06545955
What this trial is testing

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals 250
Large-scale testing (Phase 3)Active Not RecruitingNCT04452591
What this trial is testing

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
CG Oncology, Inc. 190
Testing effectiveness (Phase 2)Active Not RecruitingNCT04640623
What this trial is testing

TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Who this might be right for
Urinary Bladder Neoplasms
Janssen Research & Development, LLC 220
Large-scale testing (Phase 3)Ended earlyNCT04149574
What this trial is testing

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Who this might be right for
Urinary Bladder Neoplasms
Bristol-Myers Squibb 13
Early research (Phase 1)UnknownNCT06551233
What this trial is testing

Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 30
Next Page